| scholarly article | Q13442814 |
| P50 | author | Frederick G Hayden | Q87843428 |
| P2093 | author name string | Nobuo Hirotsu | |
| Akira Watanabe | |||
| Hiroki Sakaguchi | |||
| Takeki Uehara | |||
| Keiko Baba | |||
| Toru Ishibashi | |||
| Kenji Tsuchiya | |||
| Chisako Sato | |||
| Takao Shishido | |||
| Shinya Omoto | |||
| P2860 | cites work | Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan. | Q52682568 |
| Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. | Q55426854 | ||
| Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings | Q57025849 | ||
| In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit | Q57474158 | ||
| Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents | Q59353237 | ||
| Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018 | Q61814195 | ||
| Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa | Q64134362 | ||
| COMMITTEE ON INFECTIOUS DISEASES. Recommendations for Prevention and Control of Influenza in Children, 2017 - 2018. Pediatrics. 2017;140(4):e20172550 | Q89758414 | ||
| Population Pharmacokinetic and Exposure-Response Analyses of Baloxavir Marboxil in Adults and Adolescents Including Patients With Influenza | Q90585734 | ||
| Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza | Q91917768 | ||
| Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019 | Q92633011 | ||
| Population Pharmacokinetics of Baloxavir Marboxil in Japanese Pediatric Influenza Patients | Q93178609 | ||
| Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection | Q30408582 | ||
| Prevalence of seropositivity to pandemic influenza A/H1N1 virus in the United States following the 2009 pandemic | Q30423135 | ||
| Influenza virus resistance to neuraminidase inhibitors. | Q30428660 | ||
| Emergence and apparent transmission of rimantadine-resistant influenza A virus in families | Q30460018 | ||
| Oral oseltamivir treatment of influenza in children. | Q32064242 | ||
| Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection | Q33876428 | ||
| Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season | Q34292651 | ||
| Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. | Q36048315 | ||
| Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis | Q37955413 | ||
| Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial | Q38500366 | ||
| Influenza Vaccine Effectiveness in the United States during the 2015-2016 Season | Q40089214 | ||
| Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial | Q40152886 | ||
| Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children | Q40415936 | ||
| The course of fever following influenza virus infection in children treated with oseltamivir | Q40421191 | ||
| Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan. | Q40426705 | ||
| Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. | Q40462169 | ||
| A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. | Q42232612 | ||
| Influenza-associated pediatric deaths in the United States, 2004-2012. | Q42259236 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P577 | publication date | 2019-09-20 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes |
| Q89877245 | Favipiravir, an anti-influenza drug against life-threatening RNA virus infections |
| Q90689822 | Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility |
| Q96126746 | Modeling mitigation of influenza epidemics by baloxavir |
| Q89843860 | Next-generation direct-acting influenza therapeutics |
| Q89739869 | Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil |
| Q94570381 | Very high sensitivity of a rapid influenza diagnostic test in adults and elderly individuals within 48 hours of the onset of illness |
Search more.